Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) shares hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $6.53 and last traded at $6.50, with a volume of 388,790 shares changing hands. The stock had previously closed at $6.40.

A number of brokerages have recently issued reports on DRNA. Zacks Investment Research cut shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Chardan Capital restated a “hold” rating on shares of Dicerna Pharmaceuticals in a report on Monday, August 14th. Finally, ValuEngine cut shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $5.33.

The stock’s market cap is $130.90 million. The firm has a 50-day moving average of $4.08 and a 200-day moving average of $3.44.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings data on Thursday, August 10th. The biopharmaceutical company reported ($1.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.54). Dicerna Pharmaceuticals had a negative net margin of 8,474.12% and a negative return on equity of 168.65%. The firm had revenue of $0.25 million for the quarter, compared to analysts’ expectations of $0.08 million. During the same period last year, the company posted ($0.75) earnings per share. The business’s revenue for the quarter was up 2400.0% compared to the same quarter last year. On average, equities analysts predict that Dicerna Pharmaceuticals, Inc. will post ($2.70) EPS for the current year.

A number of hedge funds have recently made changes to their positions in DRNA. Northern Trust Corp grew its position in Dicerna Pharmaceuticals by 6.1% during the 2nd quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 2,094 shares during the last quarter. Bourgeon Capital Management LLC grew its position in Dicerna Pharmaceuticals by 188.9% during the 2nd quarter. Bourgeon Capital Management LLC now owns 39,000 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 25,500 shares during the last quarter. Paloma Partners Management Co grew its position in Dicerna Pharmaceuticals by 49.7% during the 1st quarter. Paloma Partners Management Co now owns 160,000 shares of the biopharmaceutical company’s stock valued at $544,000 after purchasing an additional 53,131 shares during the last quarter. Sabby Management LLC grew its position in Dicerna Pharmaceuticals by 100.0% during the 1st quarter. Sabby Management LLC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $680,000 after purchasing an additional 100,000 shares during the last quarter. Finally, UBS Group AG grew its position in Dicerna Pharmaceuticals by 0.6% during the 1st quarter. UBS Group AG now owns 284,645 shares of the biopharmaceutical company’s stock valued at $968,000 after purchasing an additional 1,599 shares during the last quarter. 55.49% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Dicerna Pharmaceuticals, Inc. (DRNA) Sets New 1-Year High at $6.53” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/dicerna-pharmaceuticals-inc-drna-sets-new-1-year-high-at-6-53/1611508.html.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.